

Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis

Jessica A. Hartmann^{a,b} Patrick D. McGorry^{a,b} Stefanie J. Schmidt^{c,p} G. Paul Amminger^{a,b}
Hok Pan Yuen^{a,b} Connie Markulev^{a,b} Gregor E. Berger^d Eric Y.H. Chen^e Lieuwe de Haan^f
Ian B. Hickie^g Suzie Lavoie^{a,b} Meredith J. McHugh^{a,b} Nilufar Mossaheb^h Dorien H. Nieman^f
Merete Nordentoftⁱ Anita Riecher-Rössler^j Miriam R. Schäfer^{a,b} Monika Schlögelhofer^{h,k}
Stefan Smesny^l Andrew Thompson^m Swapna Kamal Vermaⁿ Alison R. Yung^o
Barnaby Nelson^{a,b}

^aOrygen, The National Centre of Excellence in Youth Mental Health, and ^bCentre for Youth Mental Health, University of Melbourne, Melbourne, VIC, Australia; ^cUniversity Hospital of Psychiatry, University of Bern, Bern, and ^dChild and Adolescent Psychiatric Service of the Canton of Zurich, Zurich, Switzerland; ^eDepartment of Psychiatry, University of Hong Kong, Hong Kong, SAR, China; ^fDepartment of Psychiatry, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; ^gBrain and Mind Centre, University of Sydney, Sydney, NSW, Australia; ^hDepartment of Psychiatry and Psychotherapy, Clinical Division of Social Psychiatry, Medical University of Vienna, Vienna, Austria; ⁱMental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark; ^jUniversity of Basel Psychiatric Hospital, Basel, Switzerland; ^kDepartment of Child and Adolescent Psychiatry, Medical University Vienna, Vienna, Austria; ^lDepartment of Psychiatry, Jena University Hospital, Jena, Germany; ^mDivision of Mental Health and Wellbeing, Warwick Medical School, University of Warwick, Coventry, UK; ⁿInstitute of Mental Health, Singapore, Singapore; ^oInstitute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK; ^pDepartment of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany

Keywords

Cognitive-behavioural therapy · Case management · Ultra-high risk for psychosis · At-risk mental state · Early intervention

Abstract

Background: Cognitive-behavioural therapy (CBT) is the first-choice treatment in clients with ultra-high risk (UHR) for psychosis. However, CBT is an umbrella term for a plethora of different strategies, and little is known about the association between the intensity and content of CBT and the severity of symptomatic outcome. **Methods:** A sample of 268 UHR participants received 6 months of CBT with case manage-

ment (CBCM) in the context of the multi-centre NEURAPRO trial with monthly assessments of attenuated psychotic symptoms (APS). Using multilevel regressions and controlling for the initial severity of APS, the associations between (1) number of CBCM sessions received and severity of APS and (2) specific CBCM components and severity of APS were investigated. **Results:** In month 1, a higher number of sessions and more assessment of symptoms predicted an increase in APS, while in month 3, a higher number of sessions and more monitoring predicted a decrease in the level of APS. More therapeutic focus on APS predicted an overall increase in APS. **Conclusions:** Our findings indicate that the association between intensity/content of CBCM and severity of APS in a sample of UHR participants depends on the

length of time in treatment. CBCM may positively impact the severity of APS later in the course of treatment. Therefore, it would seem important to keep UHR young people engaged in treatment beyond this initial period. Regarding the specific content of CBCM, a therapeutic focus on APS may not necessarily be beneficial in reducing the severity of APS, a possibility in need of further investigation.

© 2017 S. Karger AG, Basel

Introduction

The at-risk mental state or ultra-high risk (UHR) state describes individuals identified as being at enhanced risk of developing a first episode of psychosis, based on the presence of attenuated/short-lived psychotic symptoms or a significant drop in functioning in the context of a family history of psychosis. Since the introduction of the UHR criteria [1], considerable research attention has been directed towards the development of effective interventions to positively impact on the trajectory of the UHR state. Growing evidence suggests that psychological therapies such as cognitive-behavioural therapy (CBT) may provide a safe and effective pre-emptive treatment option in UHR clients [2–7]. While recent studies suggest that both psychological and pharmacological interventions reduce rates of transition to psychosis, CBT is, given the favourable risk-benefit ratio, considered the first-choice treatment in UHR groups [8, 9].

CBT-informed therapy is an umbrella term for a plethora of different strategies that has primarily been evaluated as an overall “treatment package” [10] which, in clinical implementation, is carried out in a variety of forms [11, 12]. CBT comprises various components such as psychoeducation, case formulation, cognitive challenging, or behavioural strategies. Little is known, especially in the field of at-risk mental states, about which components of CBT are in fact delivered and if there are specific CBT “ingredients” which may be more beneficial than others [10, 13]. Furthermore, the effects of frequency or intensity of CBT (i.e., number of sessions delivered) on treatment outcome has only been partially investigated [4]. The UK-based EDIE-2 trial showed that a higher number of sessions was associated with less attenuated psychotic symptoms (APS) at the 12-month follow-up [4]. Secondary analyses based on this trial evaluated the presence of certain components in cognitive therapy from file notes and identified a greater treatment effect if case formulation and homework were part of the therapy [13]. Another study in clients with psychosis suggested that CBT

was only beneficial for those who received the full 9 months of CBT. CBT consisting exclusively of engagement or assessment was not effective, and the therapy appeared to have a detrimental effect on those who did not finish the intervention [10].

Although there is evidence for an early (first 4 weeks) rapid response to CBT for depression [14, 15], little is known regarding the role of time in treatment in the UHR population. A qualitative study in psychosis investigating clients’ experiences of case formulation in CBT suggested that the reaction may be subject to change over time: some clients experienced it initially as confrontational; however, this improved over time in most clients [16].

The current study addresses the need to identify effective components of CBT-informed therapy in UHR clients. This may help to develop more targeted and more effective treatment packages for future studies and clinical implementation.

In the present study, a UHR treatment regimen consisting of CBT delivered within a therapeutic framework of case management (CBCM) was evaluated. In CBCM, the case manager is a central clinician who both manages general aspects of the patient’s care and provides psychotherapy.

The aims of the present study were (1) to characterise the CBCM provided in this study and (2) to investigate whether the intensity of CBCM and/or specific CBCM components received predicted the severity of subsequent APS.

Based on the existing literature, it was hypothesised that a greater number of sessions would be associated with lower levels of subsequent symptomatology. Exploratory analyses regarding the specific CBCM components and time in treatment were also conducted.

Method

Study Design and Setting

This study is based on data from the NEURAPRO trial, a multi-centre, double-blind randomised controlled trial investigating the effects of omega-3 polyunsaturated fatty acids versus placebo in UHR individuals (ACTRN 12608000475347) [14, 15]. Overall, 304 participants aged 13–40 years and meeting criteria for UHR status received either omega-3 polyunsaturated fatty acids together with CBCM, or placebo with CBCM. The total study period was 12 months. All participants provided written informed consent prior to enrolment in the study. Details on the study methodology and results of the randomised controlled trial have been described in detail previously [14, 15]. The study was presented to participants as a study of the effects of a nutritional supplement (omega-3 fatty acids) in addition to a psychosocial intervention (CBCM). In other words, the psychological intervention was presented as and

viewed by participants as integral to the intervention package. No significant differences in any demographic characteristics, clinical or functional outcomes, or CBCM variables were observed between the experimental and control groups at baseline or at the 12-month follow-up [15]. No significant differences in any of these variables were observed at medium term (3.5 years; manuscript in preparation). Therefore, CBCM across both groups was used for joint analysis in the current study.

Cognitive-Behavioural Case Management

CBCM consists of CBT within a case management framework and is globally implemented in numerous UHR clinics (for details, please see the PACE Clinic Manual: A Treatment Approach for Young People at Ultra High Risk for Psychosis [16]). All clinicians were extensively trained by senior psychologists according to a study-specific CBCM manual prior to study start. The manual consists of the following modules: (1) stress management, (2) positive symptoms, (3) negative symptoms, (4) basic symptoms, and (5) comorbidity. In order to ensure treatment fidelity, regular (fortnightly) individual and group supervision was maintained. At the different sites, there was local supervision with a senior clinician as well as regular supervision with senior psychologists at the leading site (Orygen) via Skype. Sessions were audiotaped with client consent. Session dates and CBCM content were recorded using a checklist completed by the clinician after every CBCM session. The checklist was divided into 13 CBCM components (see Table 1).

Procedure

All participants received CBCM adapted to the participant's level of need and symptom profile within the first 6 months of study enrolment. Symptomatic outcome was assessed at the end of each month. Since participants received on average less than 1 CBCM session in months 5 and 6, and 80% of the sessions within the 6-month CBCM period occurred during the first 4 months, the current investigation focused on these first 4 months (month 1–4) of CBCM.

The following variables were created per individual: (1) number of sessions received (0, 1, 2, 3, 4 or more) and (2) number of times each specific component was received.

Outcome Measures

The severity of APS was operationalised as described by Morrison et al. [4]: using the Comprehensive Assessment of At-Risk Mental States (CAARMS [17]), we summed the scores of the product of global rating scale score (0–6) and frequency (0–6) of the following 4 subscales: unusual thought content, non-bizarre ideas, perceptual abnormalities, and disorganised speech.

Statistical Methods

Due to the hierarchical structure of the data (repeated measures [level 1] nested within participants [level 2], and participants nested within study sites [level 3]), analyses were conducted using the procedure “mixed” for Stata 14.0 for linear mixed models, bootstrapped with 500 replications. Additionally, we conducted a sensitivity analysis including “completers” only. A completer was defined as a participant who did not drop out, but completed all research interviews.

Number of Sessions

To investigate the association between number of sessions received and severity of APS while accounting for prior symptom-

Table 1. Components of cognitive-behavioural case management

Components	% of sessions
<i>Included in analysis</i>	
Monitoring	68.4
Stress management	51.3
Assessment of symptoms	48.2
Comorbidity	39.4
Negative symptoms	38.8
Homework	37.6
Positive symptoms	30.3
Case management	21.7
General information/psychoeducation	21.3
Basic symptoms	17.3
<i>Not included in analysis^a</i>	
Crisis management	14.4
Family work	14.4
Relapse prevention and termination	10.9

^a Excluded as these elements constituted less than 15% of the sessions.

Table 2. Baseline demographic and clinical data ($n = 268$)

Characteristic	
Age, years	18.9 ± 4.35 (13–37)
Gender	
Female	146 (54)
Male	122 (46)
Ethnicity	
Caucasian	216 (80)
Black or African American	7 (3)
Asian	35 (13)
Other	10 (4)
Education	
Primary school	105 (39)
Secondary school, discontinued	49 (18)
Secondary school, completed	71 (27)
Trade or technical training	28 (11)
Undergraduate university course	14 (5)
Missing	1 (0)
APS	37.3 ± 16.89 (0–96)
MADRS	19.3 ± 8.92 (0–39)

Values are n (%) or mean ± SD (range), as appropriate. APS, attenuated psychotic symptoms; MADRS, Montgomery-Asberg Depression Rating Scale.

atic levels, we applied the same procedure as described in Zilchamano et al. [18]. The number of sessions during a month was used to predict the subsequent severity of APS_(T), while controlling for prior severity of APS (APS_(T-1)). Additionally, we controlled for depressive symptoms, gender, age, and number of sessions already

received. As the association between the number of sessions and APS may depend on time in treatment, an interaction term between the number of sessions and the assessment time point (categorical, month 1–4) was introduced [18]. Interaction terms were removed when not significant.

CBCM Components

The same model as described above was applied to investigate the association between specific CBCM components and the severity of APS.

Components that may be related to outcome were initially identified in a univariate regression model unadjusted for the other components. Components that significantly predicted APS in the univariate models and components which constituted more than 15% of the sessions (see Table 1) were included in the full, multivariate model, adjusted for the other components. As not all CBCM components were received by all participants, each model included only those participants who received the component at least once.

Results

Of the 304 participants randomised in the parent study [15], 268 participants (88%) had at least 1 symptom assessment other than baseline, with CBCM checklist data on at least 1 session available.

Table 2 displays baseline demographic and clinical information. Participants received on average a total of 10.5 sessions (SD 6.02, range 1–32). The number of sessions per month significantly decreased over time ($p < 0.001$). The most prevalent CBCM components administered were “monitoring,” “stress management,” and “assessment of symptoms” (Table 1). The proportion of the components “general information/psychoeducation,” “monitoring,” “assessment of symptoms,” “positive symptoms,” “basic symptoms,” and “homework” decreased over time ($p < 0.01$). The proportion of “relapse prevention and termination” increased with time ($p < 0.001$). All other components remained stable.

Number of Sessions

In predicting the severity of APS, the interaction between number of sessions and assessment time point (month 1–4) was significant ($\chi^2(3) = 17.93, p < 0.001$). Using the Stata procedure Margins, the slopes per month were subsequently estimated. For month 1, there was a significant positive association between number of sessions and severity of APS: more sessions significantly predicted an increase of APS ($b = 1.61, SE = 0.59, p = 0.007, 95\% CI: 0.44, 2.78$). By month 3, a significant negative association between number of sessions and level of APS was observed: more sessions significantly predicted a de-

crease in APS ($b = -1.23, SE = 0.46, p = 0.008, 95\% CI: -2.14, -0.32$). In other words, while accounting for the initial severity of APS, each additional CBCM session attendance was associated with a 1.6 point increase in severity of APS by the end of the first month, while during month 3, each additional session attended was associated with a 1.2 point reduction of severity of APS. Sensitivity analyses using completers only ($n = 207$) yielded similar results: a positive association between number of sessions and APS in month 1 ($b = 1.67, SE = 0.69, p = 0.016, 95\% CI: 0.32, 3.02$), and a negative association in month 3 ($b = -1.20, SE = 0.46, p = 0.009, 95\% CI: -2.10, -0.30$).

CBCM Components

“Family work,” “crisis management,” and “relapse prevention/termination” were a priori excluded from analyses because these components constituted less than 15% of the CBCM sessions (see Table 1). The components “psychoeducation,” “comorbidity,” “negative symptoms,” “homework,” and “basic symptoms” were not included in the full model as they failed to show an association with APS in the univariate models.

Table 3 provides the results of the full, multivariate models. Included were the components “case management,” “monitoring,” “assessment of symptoms,” “stress management,” and “positive symptoms.” “Monitoring” and “assessment of symptoms” showed an interaction with time point, with a similar pattern to that seen for number of sessions. There was a positive association between the component “assessment of symptoms” and severity of APS during the first month (i.e., more assessment, more symptoms). For the component “monitoring,” a negative association was observed for month 3 (i.e., more monitoring, lower level of symptoms). “Stress management” and “case management” did not show a significant association with APS in the full model. The component “positive symptoms” demonstrated a positive association with APS (i.e., more focus on positive symptoms, more APS) throughout the treatment.

Discussion

Our study investigated the content and intensity of a CBCM regimen in UHR participants provided in the context of the NEURAPRO trial, both descriptively as well as in association with APS. Our findings indicate that the majority of CBCM occurred within the first 4 months of the protocol and there was substantial variation in the number of sessions received (ranging from 1 to 32 sessions), prob-

Table 3. Results for the mixed model investigating the association between cognitive-behavioural case management component and level of attenuated positive symptoms

Component	Component by time (interaction)	Coefficient (simple slopes, per month)	Coefficient (overall main effect)
APS			
Case management (n = 140)	$\chi^2(3) = 5.51$	-	b = -0.23 (0.61) [-1.44, 0.97]
Monitoring (n = 233)	$\chi^2(3) = 11.06^{**}$	Month 1: b = 0.36 (0.66) [-0.94, 1.66] Month 2: b = -1.04 (0.66) [-2.33, 0.25] Month 3: b = -1.55 (0.60) [-2.73, -0.37]** Month 4: b = 0.03 (0.83) [-1.58, 1.65]	-
Assessment (n = 215)	$\chi^2(3) = 8.01^*$	Month 1: b = 1.49 (0.59) [0.33, 2.65]** Month 2: b = 0.27 (0.76) [-1.22, 1.75] Month 3: b = -0.86 (0.85) [-2.52, 0.81] Month 4: b = 1.29 (0.96) [-0.59, 3.16]	-
Stress management (n = 229)	$\chi^2(3) = 5.38$	-	b = -0.44 (0.45) [-1.32, 0.44]
Positive symptoms (n = 174)	$\chi^2(3) = 2.63$	-	b = 1.69 (0.60) [0.51, 2.87]**

When interactions with time were not significant, the overall effect was estimated. Coefficients are expressed with SE in parentheses and 95% CI in square brackets. CBCM, cognitive-behavioural case management; APS, attenuated psychotic symptoms. *** $p < 0.001$; ** $p < 0.01$; * $p < 0.05$.

ably reflecting variation in the clients' clinical presentations and varying levels of engagement. The most frequently delivered elements of CBCM were "monitoring," "stress management," and "assessment of symptoms."

In this study, we found that a greater number of sessions predicted a higher level of APS at the end of the first 4 weeks of treatment, an association which was reversed by month 3 (i.e., more sessions was associated with lower level of APS). To our knowledge, our findings are the first to indicate that the association between "intensity" of CBCM (i.e., number of sessions received) and level of APS may depend on time in treatment. These results appear to be robust, as the same pattern was observed when a sensitivity approach was applied including completers only.

These novel findings may be interpreted in several ways. First of all, it is possible that the initial "unfavourable" CBCM-APS association is related to a form of response bias. At the beginning of the treatment, the amount of psychoeducation regarding UHR is high, potentially leading to a change in how and what experiences are revealed compared to the initial assessment. In other words, participants may be better informed, better able to describe, and potentially reveal new experiences they did not disclose at the initial assessment, leading to a higher rating of APS on the CAARMS for those who received more CBCM sessions. Alternatively, the positive associa-

tion between number of sessions and level of APS in the first 4 weeks may be driven by participants with increasing APS receiving more sessions (i.e., an increase in clinical contact in response to worsening symptoms). Similarly, the negative association between number of sessions and APS in month 3 may be driven by participants with decreasing APS receiving fewer sessions. However, the probability of this form of reverse causation has been reduced by controlling for the previous level of APS for every participant.

Conversely, and speculatively, it may be the case that at the very outset of treatment, CBCM is associated with an initial intensification of APS. In support of this, Dunn et al. [10] identified a potential negative effect of CBT in patients with psychosis who stopped the treatment prematurely. Furthermore, a qualitative study on clients' experience of CBT's case formulation suggested a change over time, with some clients experiencing it as confrontational in the beginning, but with an improvement of those feelings over time in most clients [19]. Another qualitative study investigating the subjective experiences of UHR participants of the EDIE-2 trial indicated that many clients disclosed their unusual psychological experiences for the first time in their lives [20]. Clients also suggested that talking about these experiences was challenging or difficult [18, 19]. It is conceivable that initial confrontation

with these unusual experiences at the beginning of CBCM treatment is responsible for the initial unfavourable CBCM-APS association. This is speculative and our results need to be replicated before firm conclusions can be drawn. It may reflect some traditional views of psychotherapy for psychosis [10, 20]: talking about the content of psychotic experiences was sometimes discouraged from this perspective as it could lead to an aggravation or “inadvertent collusion” [21]. Most importantly, however, our results suggest that participants may start to benefit from more sessions of CBCM when they continue treatment.

A change in therapeutic alliance may also play a role in the observed association between CBCM intensity and APS. Therapeutic alliance is defined as the quality of the relationship between client and therapist and is regarded as playing a pivotal role in the outcome of psychotherapy [22]. In a sample of people with acute first- or second-episode psychosis, Goldsmith et al. [20] showed that CBT may have detrimental effects (i.e., worse symptomatic outcome) when the therapeutic alliance is poor, and positive effects when the alliance is good. More importantly, improving the therapeutic alliance was associated with enhanced outcome [20]. In the current study, the changing association between CBCM intensity and APS may be a result of an improving therapeutic alliance over time. Finally, it is also possible that, initially, CBT is somewhat difficult for this client group to engage with, possibly due to it being an overly formalised approach that may be challenging for young people, particularly when distressed and being oriented to a new service [2]. This interpretation would suggest that a therapeutic approach that emphasises engagement, “meeting the person where they are at,” and that is possibly more supportive and person-centred in nature may be indicated in the very early phases of treatment for this group, before moving onto more concerted or focused CBT techniques.

Regarding the CBCM components, only the components “monitoring,” “assessment of symptoms,” and “positive symptoms” were significantly associated with severity of APS in the full model. “Monitoring” and “assessment” followed the same pattern as number of sessions: in interaction with time, “assessment of symptoms” was positively associated with APS (i.e., more assessment, higher level of symptoms) during the first month only, while this association changed its direction in month 3 (without reaching significance). “Monitoring” was negatively associated with APS in month 3 only (i.e., more monitoring, lower level of APS), and an investigation of the coefficients shows that also in this case, the association changed its direction compared to month 1.

The finding regarding the component “positive symptoms” followed a different pattern. More focus on positive symptoms predicted a higher level of APS across the investigated intervention period (i.e., no interaction with time). Again, this finding can be interpreted in a number of ways. First, while we control for level of APS during the previous assessment, it is still possible that participants demonstrate increasing APS in the few weeks prior to a research assessment. This may be picked up by the clinician, who responds with an increased focus on APS during CBCM sessions. Conversely and speculatively, focusing on APS may not be beneficial in decreasing its level, in line with what is discussed and reviewed above.

The fact that most other components did not show significant associations with symptomatic outcome may be due to a lack of power, and more research in larger samples is required.

As this study was a secondary analysis of the NEURAPRO trial and was not specifically designed to evaluate CBCM, it comes with the clear limitations of no control group (i.e., a group who received no CBCM or a different form of psychotherapy). Furthermore, components were not randomly assigned, but selected on the basis of participant presentation. Although the current analytical approach (i.e., controlling for previous symptomatic levels) reduced the possibility of reverse causation, we cannot ascertain cause and effect. That is, symptomatic levels may be impacted by CBCM, and CBCM may be impacted by participant presentation, or both. Furthermore, it is likely that the different components may interact in impacting on symptomatic levels and there may be order effects of the specific CBCM components. Moreover, we were not able to investigate certain components (i.e., crisis management, family intervention) as these elements were delivered infrequently. However, our exploratory study can be used to generate hypotheses to be experimentally tested in the future. In light of psychotherapeutic interventions being a preferred option to medication in young people at risk of psychotic disorder, it is important to identify the active ingredients or key components of CBT-informed therapies. Recommendations for future studies are dismantling studies or trials randomising participants to components. Furthermore, it is important to measure therapeutic alliance over the course of CBT intervention and capture the detailed subjective experience of the participants. Understanding the specific structure (e.g., duration) and content (components) of CBT that is most effective for symptoms in this patient group can critically inform future treatment.

Our findings, while preliminary, indicate that the association between intensity/content of CBCM and severity of APS in a sample of UHR participants depends on time in treatment. CBCM may positively impact APS only later in the course of treatment, after an initial refractory phase. Therefore, it may be important for clinicians to keep UHR young people engaged in treatment beyond this initial period and to increase awareness and validation of the often potentially confronting and destabilising nature of talking about and discussing APS for the first time. Alternatively, therapeutic approaches that emphasise engagement, possibly more supportive and person-centred in nature, may be indicated in the very early phases of treatment for this group. Furthermore, a therapy focus on positive symptoms may not be beneficial for all clients throughout treatment. In line with the suggestions of Richardson and Doster [23], clinicians need to carefully balance treatment along 3 dimensions of baseline risk (i.e., the risk the person would be at without treatment), expected responsiveness to treatment, and possible vulnerabilities (e.g., possible adverse effects) imposed by the treatment [24]. Future studies that randomise participants to CBCM or CBT components are needed to replicate the current findings and ascertain cause and effect.

Acknowledgements

This work was supported by a grant from the Stanley Medical Research Institute (07TGF-1102), a National Health and Medical Research Council (NHMRC) Australia Program Grant (ID: 566529; P.D.M., I.B.H., A.R.Y., and G.P.A.), and a grant from the Colonial Foundation. J.A.H. is supported by a Netherlands Organization for Scientific Research (NWO)-Rubicon Grant (825.15.015). P.D.M. was supported by a Senior Principal Research Fellowship from the NHMRC (ID: 1060996), G.P.A. and A.R.Y. were supported by NHMRC Senior Research Fellowships (ID: 1080963 and 566593), and B.N. was supported by an NHMRC Career Development Fellowship (ID: 1027532).

Disclosure Statement

P.D.M. reported receiving grant funding from the National Alliance for Research on Schizophrenia and Depression and unrestricted research funding from AstraZeneca, Eli Lilly, Janssen-Cilag, Pfizer, and Novartis, as well as honoraria for educational activities with AstraZeneca, Eli Lilly, Janssen-Cilag, Pfizer, Bristol-Myers Squibb, Roche, and the Lundbeck Institute. B.N., I.B.H., A.R.Y., and G.P.A. have received NHMRC funding. No other conflicts were reported.

References

- 1 Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A: Monitoring and care of young people at incipient risk of psychosis. *Schizophr Bull* 1996;22:283–303.
- 2 Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB: A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. *Schizophr Res* 2011;125:54–61.
- 3 McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H: Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. *Arch Gen Psychiatry* 2002;59:921–928.
- 4 Morrison AP, French P, Stewart SL, Birchwood M, Fowler D, Gumley AI, Jones PB, Bentall RP, Lewis SW, Murray GK, Patterson P, Brunet K, Conroy J, Parker S, Reilly T, Byrne R, Davies LM, Dunn G: Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. *BMJ* 2012;344:e2233.
- 5 Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, Parker S, Bentall RP: Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. *Br J Psychiatry* 2004;185:291–297.
- 6 van der Gaag M, Nieman DH, Rietdijk J, Dragt S, Ising HK, Klaassen RM, Koeter M, Cuijpers P, Wunderink L, Linszen DH: Cognitive behavioral therapy for subjects at ultra-high risk for developing psychosis: a randomized controlled clinical trial. *Schizophr Bull* 2012;38:1180–1188.
- 7 Hutton P, Taylor PJ: Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. *Psychol Med* 2014;44:449–468.
- 8 van der Gaag M, Smit F, Bechdolf A, French P, Linszen DH, Yung AR, McGorry P, Cuijpers P: Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. *Schizophr Res* 2013;149:56–62.
- 9 Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, Maric NP, Salokangas RK, Riecher-Rossler A, van der Gaag M, Meneghelli A, Nordentoft M, Marshall M, Morrison A, Raballo A, Klosterkötter J, Ruhrmann S: EPA guidance on the early intervention in clinical high risk states of psychoses. *Eur Psychiatry* 2015;30:388–404.
- 10 Dunn G, Fowler D, Rollinson R, Freeman D, Kuipers E, Smith B, Steel C, Onwumere J, Jolley S, Garety P, Bebbington P: Effective elements of cognitive behaviour therapy for psychosis: results of a novel type of subgroup analysis based on principal stratification. *Psychol Med* 2012;42:1057–1068.
- 11 Birchwood M, Trower P: The future of cognitive-behavioural therapy for psychosis: not a quasi-neuroleptic. *Br J Psychiatry* 2006;188:107–108.
- 12 Turkington D, Kingdon D, Chadwick P: Cognitive-behavioural therapy for schizophrenia: filling the therapeutic vacuum. *Br J Psychiatry* 2003;183:98–99.

- 13 Flach C, French P, Dunn G, Fowler D, Gumley AI, Birchwood M, Stewart SL, Morrison AP: Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE-2 trial. *Br J Psychiatry* 2015;207:123–129.
- 14 Markulev C, McGorry PD, Nelson B, Yuen HP, Schaefer M, Yung AR, Thompson A, Berger G, Mossaheb N, Schlogelhofer M, Smesny S, de Haan L, Riecher-Rossler A, Nordentoft M, Chen EY, Verma S, Hickie I, Amminger GP: NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. *Early Interv Psychiatry* 2015, Epub ahead of print.
- 15 McGorry P, Nelson B, Markulev C, Yuen H, Schaefer M, Mossaheb N, Smesny S, Schlogelhofer M, Hickie I, Berger G, Chen E, de Haan L, Nieman D, Nordentoft M, Riecher-Roessler A, Verma S, Thompson A, Yung A, Amminger G: Neurapro: A multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders. *JAMA Psychiatry* 2016, in press.
- 16 Pace Manual Writing Group: The Pace Clinic Manual: A Treatment Approach for Young People at Ultra High Risk of Psychosis. Melbourne, Orygen, the National Centre of Excellence in Youth Mental Health, 2012.
- 17 Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell'Olio M, Francey SM, Cosgrave EM, Killackey E, Stanford C, Godfrey K, Buckby J: Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. *Aust NZ J Psychiatry* 2005;39:964–971.
- 18 Zilcha-Mano S, Roose SP, Barber JP, Rutherford BR: Therapeutic alliance in antidepressant treatment: cause or effect of symptomatic levels? *Psychother Psychosom* 2015;84:177–182.
- 19 Morberg Pain C, Chadwick P, Abba N: Clients' experience of case formulation in cognitive behaviour therapy for psychosis. *Br J Clin Psychol* 2008;47:127–138.
- 20 Byrne RE, Morrison AP: Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. *Psychol Psychother* 2014;87:357–371.
- 21 Goldsmith LP, Lewis SW, Dunn G, Bental RP: Psychological treatments for early psychosis can be beneficial or harmful, depending on the therapeutic alliance: an instrumental variable analysis. *Psychol Med* 2015;45:2365–2373.
- 22 McCabe R, Priebe S: Communication and psychosis: it's good to talk, but how? *Br J Psychiatry* 2008;192:404–405.
- 23 Martin DJ, Garske JP, Davis MK: Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review. *J Consult Clin Psychol* 2000;68:438–450.
- 24 Richardson WS, Doster LM: Comorbidity and multimorbidity need to be placed in the context of a framework of risk, responsiveness, and vulnerability. *J Clin Epidemiol* 2014;67:244–246.
- 25 Fava GA, Guidi J, Rafanelli C, Sonino N: The clinical inadequacy of evidence-based medicine and the need for a conceptual framework based on clinical judgment. *Psychother Psychosom* 2015;84:1–3.